Biotech · Private company
Criterium, Inc.
Track this companyFree. Adds Criterium, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials155 recruiting or active
Pipeline programs21From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline21
- AbemaciclibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Adjuvant TherapyPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AlpelisibPhase 2 · HER2-positive Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AMG 510Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- brigatinibPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarfilzomibPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- ElacestrantPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- EribulinPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FruquintinibPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Fruquintinib+ Lonsurf (trifluridine and tipiracil)Phase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 2 · HER2-positive Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- MVASIPhase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- OxaliplatinPhase 2 · Colorectal Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- PalbociclibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PomalidomidePhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- TepotinibPhase 2 · Advanced Non-Small Cell Lung Cancer With MET MutationsClinicalTrials.gov · fetched Nov 12, 2026
- TrastuzumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TucatinibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- TucatinibPhase 2 · HER2-positive Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials15
- A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal CancerPHASE2 · RECRUITING · started Oct 27, 2025ClinicalTrials.gov NCT06992258 · fetched Nov 12, 2026
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBCPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2024ClinicalTrials.gov NCT05458674 · fetched Nov 12, 2026
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 25, 2022ClinicalTrials.gov NCT05230810 · fetched Nov 12, 2026
- Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerPHASE2 · TERMINATED · started Jul 28, 2022ClinicalTrials.gov NCT05167409 · fetched Nov 12, 2026
- A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain MetastasisPHASE1_PHASE2 · WITHDRAWN · started Jun 15, 2022ClinicalTrials.gov NCT05180422 · fetched Nov 12, 2026
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCPHASE1_PHASE2 · TERMINATED · started May 25, 2022ClinicalTrials.gov NCT04739358 · fetched Nov 12, 2026
- Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast CancerPHASE1_PHASE2 · TERMINATED · started Apr 21, 2022ClinicalTrials.gov NCT04791384 · fetched Nov 12, 2026
- Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 23, 2021ClinicalTrials.gov NCT04963283 · fetched Nov 12, 2026
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 9, 2021ClinicalTrials.gov NCT04567420 · fetched Nov 12, 2026
- FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal CancerPHASE2 · UNKNOWN · started Dec 2, 2019ClinicalTrials.gov NCT04169347 · fetched Nov 12, 2026
- Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other DiseasesCOMPLETED · started Feb 22, 2018ClinicalTrials.gov NCT03389399 · fetched Nov 12, 2026
- Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast CancerPHASE1_PHASE2 · COMPLETED · started Nov 27, 2017ClinicalTrials.gov NCT03054363 · fetched Nov 12, 2026
- Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsPHASE2 · TERMINATED · started Mar 9, 2017ClinicalTrials.gov NCT02706626 · fetched Nov 12, 2026
- Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular CorrelatesPHASE2 · COMPLETED · started Dec 30, 2016ClinicalTrials.gov NCT02723331 · fetched Nov 12, 2026
- A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaPHASE1_PHASE2 · TERMINATED · started Nov 1, 2011ClinicalTrials.gov NCT01464034 · fetched Nov 12, 2026